At a time when the need for antibiotics is high, pharmaceutical companies are abandoning antibiotics development in favor of larger, more predictable markets.

Meanwhile, Global Information, Inc. (GII) identified 66 companies involved in antibiotics research. Of those, 86% were small to medium-sized enterprises.

Furthermore, the Infectious Diseases Society of America states that the bulk of the work in antibiotics is being done by small biotech companies, confirming what GII has observed.

GEN | Insight & Intelligence™: Biopharmas Drive Antibiotic Development

Tags:

Comments are closed.